Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
I'm LongbridgeAI, I can summarize articles.Palisade Bio shareholders approved charter amendments to increase authorized common shares from 300 million to 450 million at the June 10, 2026 annual meeting. Other approvals included director elections, auditor ratification, executive pay votes, and equity plan updates. The amendment became effective immediately in Delaware. Analyst ratings remain mixed, with a Buy recommendation at $7.00 target, while AI analysis rates PALI as Neutral due to weak financials despite a solid balance sheet.
Palisade Bio ( (PALI) ) just unveiled an announcement.
At its annual meeting on June 10, 2026, Palisade Bio stockholders approved all seven proposals on the ballot, including the election of four directors to serve until the 2027 meeting and ratification of Baker Tilly US, LLP as independent auditor for the 2026 fiscal year. Shareholders also backed an advisory vote on executive pay and approved equity awards for non-employee directors, signaling broad support for the current leadership and compensation structures.
Investors voted to amend the company’s charter to increase authorized common shares from 300 million to 450 million, raising total authorized capital to 457 million shares. The amendment was filed in Delaware on June 11, 2026, and became effective immediately, providing Palisade Bio with expanded flexibility for future capital raising and stock-based programs, as further reinforced by approval of the amended 2021 equity incentive and employee stock purchase plans.
The most recent analyst rating on (PALI) stock is a Buy
with a $7.00 price target.
To see the full list of analyst forecasts on Palisade Bio stock,
see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and ongoing cash burn) and soft near-term technicals (below key short/intermediate moving averages with negative MACD). A solid low-leverage balance sheet and a positive partnership plus $3.0M financing provide some offset, but valuation is not supportive given continuing losses and no dividend.
To see Spark’s full report on PALI stock,
click here.
More about Palisade Bio
Palisade Bio, Inc. operates in the biopharmaceutical sector, focusing on the development of therapeutics in the life sciences industry. The company’s equity and employee stock purchase plans indicate a reliance on stock-based incentives to attract and retain talent, reflecting a growth-oriented strategy within a competitive market for biotech human capital.
Average Trading Volume: 3,696,390
Technical Sentiment Signal: Sell
Current Market Cap: $291.6M